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Objectives: To examine the outcome and prognostic factors of in-hospital mortality in patients
with acute respiratory failure (ARF) caused by Pneumocystis pneumonia (PCP) admitted to a
medical intensive care unit.
Methods: A retrospective reviewwas conducted of all patients with ARF from PCP in Ramathibodi
Hospital between 2000 and 2006. Patient characteristics, clinical presentation, and laboratory,
radiological and microbiological findings, as well as therapy and clinical course were included in
the analysis of prognostic factors of death.
Results: A total of 14 HIV-infected and 30 otherwise immunosuppressed patients were identified.
The overall mortality rate was 63.6%. Logistic regression analysis demonstrated that APACHE II
score on day 1 and level of PEEP used on day 3 of respiratory failure were associated with higher
hospital mortality. In a comparison between the HIV group and the non-HIV group, the early
mortality rate was significantly higher in the HIV group, but late hospital mortality was not
different between the two groups. Using a univariate logistic regression model, four parameters
were found to be significantly associated with death in the HIV group: sex, APACHE II score on day
1, CMV co-infection, and level of PEEP on day 3 of ARF. In the non-HIV group, corticosteroid use
prior to diagnosis of PCP and level of PEEP on day 3 of ARF were found to be the significant
parameters.
Conclusion: The mortality rate in patients with ARF caused by PCP was high. Various variable
factors were related to a poor prognosis. For improved survival, multimodality treatments are
needed to reduce these risk factors.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +66 2 201 1619.
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Pneumocystis pneumonia (PCP), the disease caused by Pneu-
mocystis jirovecii, emerged as an important cause of mor-
bidity andmortality in HIV-infected patients from early in the
AIDS epidemic.1,2 Currently, with the use of highly activePublished by Elsevier Ltd. All rights reserved.
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lactic agents to persons at high clinical risk,3 and the avail-
ability of more sensitive immunofluorescence methods of P.
jirovecii detection,4 the overall incidence of PCP cases and
survival following PCP in AIDS patients has generally
improved.5 In spite of this, the high mortality of patients
requiring mechanical ventilation (MV) has remained
unchanged, ranging from 50% to 60%.6
In contrast to AIDS-related cases, cases of PCP in patients
with other predisposing immunodeficiency states, such as
organ transplant recipients, patients with hematologic and
solid tumors receiving chemotherapeutic agents, and persons
with chronic inflammatory diseases requiring prolonged use
of corticosteroids, may be increasing,7 and the associated
mortality may be >50%.7,8 However, the previous literature
on both HIV- and non-HIV-related PCP has indicated that the
mortality of patients with acute respiratory failure (ARF)
requiring MV does not differ widely and ranges between
40% and 60%, despite the use of new aggressive supportive
interventions and monitoring.6,9—12
In order to examine the outcome and prognostic factors of
in-hospital mortality in patients with ARF requiring MV
caused by PCPat our institution, we retrospectively collected
data for PCP patients requiring MVand admitted to a medical
intensive care unit (ICU) between 2000 and 2006. Clinical,
laboratory, and radiologic features, as well as mechanical




We performed a retrospective analysis on all consecutive
patients 15 years of age with a microbiologically confirmed
diagnosis of PCP, who were admitted to the medical ICU of
Ramathibodi Hospital, a tertiary university referral hospital
in Bangkok, Thailand, and required treatment for ARF with
MV between January 1, 2000 and November 30, 2006. All
cases of PCP included in the study had cytologic documenta-
tion of the organisms by immunofluorescence or Giemsa
staining in specimens of bronchoalveolar lavage (BAL) fluid
or transbronchial biopsy (TBBX) specimens. Cases of pre-
sumptive diagnosis of PCP were not included. The study
protocol was approved by the Ethics Committee on Human
Experimentation of Ramathibodi Hospital, Faculty of Medi-
cine, Mahidol University.
Data collection
Clinical data abstracted included the following: general
demographic information, HIV status, underlying immuno-
suppressive condition, including medications and PCP pro-
phylaxis, laboratory analysis, radiology, microbiology,
APACHE (acute physiology and chronic health evaluation) II
score on the day of ARF, mechanical ventilation parameters,
antibiotic and steroid therapy, and hospital and ICU length of
stay (LOS), as well as overall hospital mortality.
In our ICU, to ventilate any patient who developed acute
respiratory failure with diffuse bilateral lung diseases, we
routinely used a tidal volume of 8—10 ml per kilogram ofpredicted body weight and optimal positive end-expiratory
pressure (PEEP) by lung mechanics as described by Suter
et al.13 With this technique, the PEEP was increased sequen-
tially with a consistent tidal volume, and the static compli-
ance wasmeasured at each interval. Optimal PEEP, defined as
the level of PEEP corresponding to maximal compliance, was
chosen. The level of optimal PEEP was titrated once daily and
recorded for three consecutive days. A plateau pressure of
30—35 cmH2O was allowed.
Statistical analysis
All values were expressed as the mean  standard deviation
(SD) for continuous variables and percent for categorical
variables. To determine the association of independent vari-
ables with hospital mortality, continuous variables were
compared using the Student’s two-tailed t-test or nonpara-
metric Mann—Whitney U-test, in case of distribution not
being normal. The Chi-square test or the Fisher’s exact test,
in case of low expected frequencies, was used for compar-
isons of categorical variables. Variables identified as signifi-
cant in the univariate analysis were assessed as predictors of
mortality using logistic regression analysis. Then, subgroup
analysis in both the HIV group and non-HIV-related PCP group
was performed to find the prognostic factors associated with
hospital mortality in the same manner. In-hospital survival
was assessed by Kaplan—Meier methods, and differences
between the HIV group and the non-HIV-related PCP group
were assessed by the log-rank test. All statistical tests were
two-sided, and p < 0.05 was considered statistically signifi-
cant. All data were analyzed with a statistical software




A total of 44 confirmed cases of PCP in adult patients who
developed ARF and required treatment with MV were identi-
fied during the period between January 1, 2000 and November
30, 2006. PCP was diagnosed by BAL in 41 out of 44 patients,
while 13 cases were diagnosed by TBBX. Fourteen cases were
HIV-seropositive and 30 cases had other conditions associated
with immunosuppression. Of these 44 patients, 27 were
female. The mean age of the patients was 46.3 years. The
meanAPACHE II scoreonday1was22.3 (Table1).Themean ICU
and hospital LOS were 18 days and 25 days, respectively.
Immunosuppressive conditions
In the HIV group, seven (50%) were female and the mean age
was 35.2 years. Of the 14 patients, 10 had been tested for
CD4 count and the mean result was 53.1 cells/ml. Only one
case had received trimethoprim/sulfamethoxazole (TMP/
SMZ) prophylaxis.
In the non-HIV group, 20 (66.7%) were female and the
mean age was 51.5 years. The underlying diseases of the
conditions associated with immunosuppression are presented
in Table 1. Eight patients had received systemic corticoster-
oids only. Two patients were treated with cytotoxic che-
Table 1 Clinical characteristics of 44 patients with Pneumocystis pneumonia-related acute respiratory failure
Variables Total (N = 44) Patients who
survived (N = 16)
Patients who
died (N = 28)
p-Value
Age, years 46.3 (14.6) 47.4 (13.4) 45.7 (15.4) 0.717
Sex, female, n (%) 27 (61.4) 7 (25.9) 20 (74.1) 0.017
Underlying immune defect, n (%)
HIV 14 (31.8) 6 (42.9) 8 (57.1) 0.541
Non-HIV 30 (68.2)
Hematologic malignancy 10 (22.7) 4 (40.0) 6 (60.0)
Connective tissue disease 16 (36.4) 4 (25.0) 12 (75.0)
Miscellaneous 4 (9.1) 2 (50.0) 2 (50.0) 0.549
Immunosuppressive drug, n (%) (N = 30)a
Corticosteroids alone 8 (26.7) 3 (37.5) 5 (62.5)
Chemotherapy alone 2 (6.7) 1 (50.0) 1 (50.0)
Combined steroids + chemotherapy 20 (66.7) 6 (30.0) 14 (70.0) 0.814
CD4, cells/ml (n = 10)
b 53.1 (47.2) 54.6 (56.3) 50.7 (37.3) 0.907
PED before ARF, mg (n = 24) c 41.5 (16.5) 34.1 (20.1) 44.0 (15.0) 0.014
Duration PED before ARF, months (n = 24) c 4.1 (3.0) 5.6 (4.9) 3.6 (2.0) 0.361
Duration before treatment, days 6.9 (5.3) 5.8 (4.1) 7.5 (5.9) 0.329
Duration before ARF, days 9.7 (6.4) 9.3 (5.9) 10.0 (6.7) 0.737
Duration from treatment to ARF, days (n = 29)d 5.0 (4.1) 3.8 (3.6) 5.8 (4.4) 0.197
LDH, U/l 632.7 (239.2) 606.9 (247.6) 646.3 (240.4) 0.681
APACHE II score 22.3 (4.9) 19.8 (4.8) 23.6 (4.4) 0.016
Anti-PCP drug, n (%)
TMP/SMZ 36 (81.8) 13 (36.1) 23 (63.9)
Clindamycin + primaquine 4 (9.1) 1 (25.0) 3 (75.0)
TMP/SMZ! clindamycin + primaquine 4 (9.1) 2 (50.0) 2 (50.0) 0.761
PED treatment, mg 66.8 (31.5) 60.6 (31.7) 70.3 (31.4) 0.331
Lung mechanics
Compliance, ml/cmH2O 24.7 (6.6) 27.3 (7.5) 23.5 (6.3) 0.372
PaO2:FiO2, mmHg 173.4 (91.5) 187.0 (72.5) 166.9 (100.0) 0.523
PEEP day 1, cmH2O 5.9 (1.8) 4.9 (1.4) 6.5 (1.8) 0.004
PEEP day 2, cmH2O 6.1 (1.8) 5.3 (0.8) 6.6 (2.1) 0.008
PEEP day 3, cmH2O 6.3 (1.8) 5.3 (1.0) 6.9 (1.9) 0.001
Respiratory co-pathogen, n (%)
Bacterial 21 (47.7) 8 (38.1) 13 (61.9) 0.820
Tuberculosis 7 (15.9) 2 (28.6) 5 (71.4) 0.640
Cytomegalovirus 15 (34.1) 4 (26.7) 11 (73.3) 0.336
Fungus 4 (9.1) 0 (0.0) 4 (100.0) 0.113
Strongyloides 3 (6.8) 0 (0.0) 3 (100.0) 0.175
Other 8 (18.2) 4 (50.0) 4 (50.0) 0.375
Pneumothorax, n (%) 16 (36.4) 4 (25.0) 12 (75.0) 0.236
Data are presented as mean (SD) or n (%).
PCP, Pneumocystis pneumonia; PED, prednisolone-equivalent dose; ARF, acute respiratory failure; LDH, lactate dehydrogenase; TMP/SMZ,
trimethoprim/sulfamethoxazole; PEEP, positive end-expiratory pressure.
a All 30 patients who received immunosuppressive drugs were in the non-HIV group.
b Ten out of 14 in the HIV group had CD4 cell count results.
c All 24 patients who had received prednisolone prior to the diagnosis of PCP were in the non-HIV group.
d The 29 patients who had received anti-PCP medication prior to acute respiratory failure.
Acute respiratory failure due to Pneumocystis pneumonia 61motherapy not containing corticosteroids, and the remainder
had received a combination of both corticosteroids and
chemotherapy. The mean prednisolone-equivalent dose
(PED) and duration of corticosteroid use prior to diagnosis
of PCP was 41.5 mg and 4.1 months, respectively. No one was
given prophylactic medications for PCP prior to onset of
pneumonia.Clinical symptoms
The mean duration of symptoms prior to ARF was about 9.7
days and was found to be significantly longer in the HIV group
(13.1  5.7 vs. 8.1  6.1 days for the HIV group and the non-
HIV group, respectively; p = 0.015). Twenty-nine patients had
received anti-PCP medication prior to ARF with a mean
Figure 1 Kaplan—Meier estimate of overall survival for
patients with acute respiratory failure caused by Pneumocystis
pneumonia.
Figure 2 Kaplan—Meier plot of survival for HIV patients and
non-HIV patients with acute respiratory failure caused by Pneu-
mocystis pneumonia.
62 V. Boonsarngsuk et al.duration of 5 days. Despite no statistical significance, the
duration from anti-PCP treatment to ARF in those who sur-
vived was less than in those who died (3.8  3.6 vs. 5.8  4.4
days; p = 0.197). All patients in the HIV group had received
anti-PCP medication prior to ARF, while only 15 of the 30
patients in the non-HIV group had received it.
Laboratory and radiographic features
The mean lactate dehydrogenase (LDH) was 632.7 U/l. No
one had an LDH value within the normal range. No significant
difference was detected in the value of LDH between the HIV
and non-HIV groups.
As expected, chest radiographic examinations generally
revealed diffuse interstitial and ground-glass appearance on
the day of ARF. However, perihilar and basal interstitial
infiltration were present in 9.1% of all cases when they
developed ARF, and all of them were in the non-HIV group.
Subsequent chest radiographs in all patients identified 16
patients with pneumothorax over the course of their ICU stay.
Co-pathogens
Co-pathogens identified from BAL or TBBX are presented in
Table 1. Cytomegalovirus (CMV) infection was diagnosed
in 15 patients, nine by demonstration of cytomegalic
intranuclear inclusions in TBBX specimens and six by posi-
tive PCR results for CMV-DNA (the AMPLICOR CMV test;
Roche Diagnostics, Branchburg, NJ, USA) in BAL fluid
obtained at the time of the diagnosis of PCP. Tuberculosis
was found as co-pathogen in seven patients. Furthermore,
Strongyloides infection was found in three patients and all
of them died.
Fungus was present in BAL fluid in four patients: Candida
albicans in two patients (one in the HIV group and the other in
the non-HIV group), Aspergillus spp in one in the non-HIV
group, and Cryptococcus neoformans in one in the HIV group.
Positive respiratory specimen results of Candida were
deemed to be secondary to colonization rather than active
disease.
Treatment and lung mechanics
Forty of the 44 patients were treated with TMP/SMZ.
Because the physician suspected TMP/SMZ-resistant PCP
infection, four of these 40 patients had their initial anti-
microbial therapy changed to clindamycin—primaquine. As
there was no pentamidine available at our hospital during
this period, four patients who had a history of suspected
allergy to TMP/SMZ received clindamycin—primaquine
instead. All patients were additionally treated with adjunc-
tive corticosteroids. Themean PED of corticosteroids used in
the treatment for ARF related to PCP in these patients was
66.8 mg.
The mean duration of MV requirement was 14.9 days. The
levels of PEEPapplied on the first three days of ARF are shown
in Table 1. Although it did not reach statistical significance,
the level of PEEP applied on day 3 was higher in non-HIV
patients (6.6  2.0 vs. 5.7  1.0 cmH2O; p = 0.087). The
mean lung compliance was 24.7 ml/cmH2O. The mean ratio
of PaO2 to fraction of inspired oxygen was 173.4, with 12
(27.3%) patients having a ratio >200.Outcomes
The overall in-hospital mortality rate for the 44 identified
cases was 63.6% (Figure 1). In the first 7 days after ARF, the
mortality rate was significantly higher in the HIV group
(mortality 14.3% vs. 0%; log rank p = 0.025) (Figure 2). How-
ever, the in-hospital mortality rate was higher in the non-HIV
group, although without statistical significance (66.7% vs.
57.1%; log rank p = 0.606).
Logistic regression analysis
Statistical analyses were performed to identify clinical
features associated with mortality. Using univariate ana-
lyses, clinical features associated with mortality are pre-
sented in Table 1. Three parameters were proved to be
significantly associated with death from PCP: female gen-
der ( p = 0.017), APACHE II score on day 1 ( p = 0.016), and
level of PEEP on all of the first three days of ARF ( p = 0.004,
Table 2 Odds ratios for variables independently associated
with an increased risk of death; multivariate analysis
Variables OR (95% CI) p-Value
APACHE II scores 1.247 (1.012—1.537) 0.039
PEEP day 3, cmH2O 2.741 (1.136—6.613) 0.025
OR, odds ratio; CI, confidence interval; PEEP, positive end-expira-
tory pressure.
Acute respiratory failure due to Pneumocystis pneumonia 630.008, and 0.001, respectively). In the multivariate
approach, only APACHE II score on day 1 and level of PEEP
on day 3 remained independently associated with lethal
outcome (Table 2).
Although age was significantly higher in the non-HIV group
( p < 0.001), it was not an influence on mortality ( p = 0.131).
In the HIV group, using a univariate logistic regression model,
sex, APACHE II score on day 1, level of PEEP on day 3, and CMV
co-infection were independent predictors of survival,
whereas history of prior use of corticosteroid, duration of
symptoms before treatment, level of PEEP on day 3, and the
subsequent development of pneumothorax were found to be
independent predictors of survival in the non-HIV group
(Table 3). Although it did not attain statistical significance,
the non-survivors had higher APACHE II scores on day 1 than
survivors in the non-HIV group (24.0  5.1 vs. 21.4  5.2;
p = 0.228). In a multivariate logistic regression model, in the
non-HIV group, the results indicated only two clinical para-
meters that were independently associated with hospital
mortality. They were history of prior use of corticosteroid
and level of PEEP on day 3 (Table 4). Because of small
numbers in the HIV group, multivariate analysis was not
performed.Table 4 Multivariate analysis of independent factors associated
Variables OR
Prior use of corticosteroid 15.4
Level of PEEP day 3, cmH2O 2.6
Pneumothorax 14.2
OR, odds ratio; CI, confidence interval; PEEP, positive end-expiratory
Table 3 Univariate analysis for independent factors associated w
patients
Variables Patients who su
HIV group (n = 14) 6 (42.9)
Sex, female, n (%) 1 (14.3)
APACHE II score 17.0 (2.4)
Level of PEEP day 3, cmH2O 5.1 (0.4)
CMV co-pathogen, n (%) 0 (0.0)
Non-HIV group (n = 30) 10 (33.3)
Prior used corticosteroid, n (%) 6 (25.0)
Duration before treatment, days 4.2 (3.0)
Level of PEEP day 3, cmH2O 5.4 (1.2)
Pneumothorax, n (%) 1 (10)
Data are presented as mean (SD) or n (%).
PEEP, positive end-expiratory pressure; CMV, cytomegalovirus.Discussion
PCP is an opportunistic infection that is associated with
substantial morbidity and mortality even when it is properly
treated.8,9 Recently, the frequency of ARF due to PCP has
been reported to be decreasing. This may be as a result of
early diagnosis and treatment, including the early use of
adjunctive corticosteroids prior to ICU admission.14 Unfortu-
nately, the case—fatality rate for mechanically ventilated
patients has increased, suggesting that the development of
respiratory failure despite maximal therapy, including corti-
costeroids, carries an extremely poor prognosis. In our series,
the mortality rate in patients with ARF requiring MV caused
by PCP was 63.6%, which is comparable to previous stu-
dies.6,15,16 Although early mortality was higher in the HIV
group, hospital mortality between the HIV and non-HIV
groups was not statistically different. This finding is consis-
tent with the previous reports of Mansharamani et al.6 and
Ewig et al.17
PCP was diagnosed by BAL alone in 93% of our patients.
Broaddus et al.18 found BAL alone had high diagnostic yields.
Because of this, some authors recommend it be done without
biopsy in HIV patients with a high suspicion for PCP.19 The
yield of BAL in patients on prophylaxis with aerosolized
pentamidine has been reported to be decreased;20 in these
cases, BAL or TBBX, or both, performed in areas of radio-
graphic findings should be considered. In our series, only one
case had had anti-PCP prophylaxis with TMP/SMZ and BALwas
able to diagnose PCP. None received aerosolized pentami-
dine.
In our study, we found that elevated APACHE II score on
day 1 and level of PEEP on day 3 were independently asso-
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64 V. Boonsarngsuk et al.PCP. In agreement with our series, Forrest et al.11,16 and
Benson et al.21 also found that APACHE II could predict the
mortality in patients with HIV-related PCP and respiratory
failure. In contrast, in our patients, APACHE II score on day 1
was not found to be a significant variable associated with
hospital outcome in non-HIV PCP. To the best of our knowl-
edge, there has been no report demonstrating APACHE II
score to predict the mortality in non-HIV PCP. In a study by
Torres et al.,22 by using univariate analysis, high APACHE II
score was found to be one of the predictors of death. How-
ever, using multivariate analysis, it could not be identified as
an independent predictor of death. The updated APACHE III
was designed to estimate the probability of in-hospital mor-
tality for adult ICU patients,23 and the findings of Festic
et al.15 showed that APACHE III scores were predictive of
mortality among non-HIV patients with PCP.
The level of PEEP applied as a predictor of hospital out-
come has been reported by others.24—26 Furthermore, Peruzzi
et al.25 found that the level of PEEP required begins to
decrease after approximately 72 hours of ICU care in the
survivor group, whereas the non-survivor group demon-
strated the need for continued escalation of support. In
the earliest stage of disease course, the histology in the lung
shows only intra-alveolar exudates and minimal inflamma-
tion. Progression to the chronic, organizing phase of diffuse
alveolar damage is common, and evidence of interstitial and
intraluminal fibrosis are present. In the late stage, extensive
septal thickening with fibrosis is found with much less alveo-
lar exudates.19,27 This results in recruitable and non-recrui-
table units under PEEP application. With the technique to
determine the optimal PEEP as described by Suter,13 the
higher the level of PEEP achieved, the more the alveolar
process is represented and, on the other hand, the lower the
level of PEEP achieved, the more the restrictive process is
represented. So, in our patients, the higher level of PEEP
applied on day 3 may represent the ongoing disease process
despite standard treatment, which resulted in fatal out-
come, whereas the lower level of PEEP applied on day 3
may represent change to a chronic process.
In HIV-related PCP with ARF, the identifiable different
variables between the survivors and non-survivors other
than APACHE II score on day 1 and level of PEEP applied on
day 3 were sex and CMV co-infection. Various studies have
confirmed that patients with concomitant CMV infections
have a higher mortality rate as compared with patients
with PCP alone;28—30 however, these studies were con-
ducted after the introduction of adjunctive corticosteroid
treatment in patients with severe PCP. Jensen et al.30
showed that CMV-positive patients treated with adjunctive
corticosteroids have a worse vital prognosis than CMV-
positive patients without corticosteroid treatment. Corti-
costeroid therapy may result in a more rapid development
of CMV disease in HIV-infected patients and thus the
clinical importance of concomitant CMV infection in PCP
has changed.31
For those who developed ARF in the non-HIV-related PCP
group, the level of PEEPon day 3 as well as history of prior use
of corticosteroid were associated with hospital mortality.
Previous studies have demonstrated prior use of corticoster-
oids as a risk of death in these patients,32,33 and a resultant
high mortality rate.6,14,17 Several mechanisms have been
postulated to explain the role of steroids in promoting thedevelopment of P. jirovecii including CD4+ lymphocyte deple-
tion and immune dysfunction.9
The subsequent development of pneumothorax was asso-
ciated with mortality in univariate analysis; however, it was
not found to be a significant factor when using multivariate
analysis. Development of pneumothorax complicating PCP is
thought to represent a poor prognosis.15,24,34 In a study by
Festic et al.,15 all of their non-HIV-related PCP and ARF
patients who developed pneumothorax died, compared to
a 90% mortality rate in our patients.
Because of the high mortality in patients with ARF requir-
ing MV caused by PCP and the fact that it is not possible to
distinguish which of these patients will or will not survive to
hospital discharge based on information routinely available
before ICU admission, we agree with the use of anti-PCP
prophylaxis in both the HIV- and non-HIV patients who are at
high risk of developing PCP. Although the clinical significance
of prophylaxis for PCP remains controversial in non-HIV
patients, some authors have suggested that immunosuppres-
sion induced by chemotherapy or radiotherapy, or patients
with inflammatory diseases receiving glucocorticosteroids
20 mg/day or more for 4 weeks or more should receive
prophylaxis.32,35,36 Furthermore, strongyloidiasis and CMV
disease should be considered as co-infections in these
patients, and aggressive work-up may be required in cases
who are not improving despite maximal therapy. Protective
lung ventilation strategies in mechanical ventilated patients
should be used to prevent pneumothorax and other ventila-
tor-associated lung injury.37
There are several limitations to this study. The number of
patients studied is relatively small. Presently, with the use of
HAART, the prescription of prophylactic agents to persons at
high clinical risk, and empirical treatment for patients with
clinically suspected PCP, the overall incidence of PCP cases
with ARF is reduced, especially in AIDS patients. Further-
more, only microbiologically confirmed cases were eligible.
Although, in our study, we evaluated the role of many prog-
nostic variables, only three prognostic factors were proved to
be significantly associated with death in univariate analysis
and included in the logistic model. Nevertheless, the main
prognostic factors identified in this study are statistically
significant, correlate with findings of previous investiga-
tions,11,16,21,24—26 and are clinically plausible. Pooling of data
from several centers could add statistical power to an ana-
lysis of prognostic markers of poor outcome.
Another limitation is related to the retrospective nature
of this review. It remains possible that some important
variables may not have been recorded. However, we believe
this to be unlikely, since the data set analyzed for each
significant prognostic factor was nearly complete (100% data
availability for gender, level of PEEP, history of prior use of
corticosteroid, duration of symptoms before treatment, and
the subsequent development of pneumothorax and 91% data
availability for APACHE II scores).
Finally, our ventilator management was perhaps not the
best and was open to debate. Even though optimal PEEP was
applied, the low tidal volume strategy was not used. The
Acute Respiratory Distress Syndrome Network demonstrated
that mechanical ventilation with a lower tidal volume (6 ml
per kilogram of predicted body weight) than is traditionally
used (12 ml per kilogram of predicted body weight) results in
decreased mortality.38 However, when plateau pressure was
Acute respiratory failure due to Pneumocystis pneumonia 65not high, a tidal volume of 7 ml/kg was found not to be
associated with lower mortality compared with a tidal
volume of 10 ml/kg.39,40 Nevertheless, the widespread belief
that tidal volume reduction is without benefit when plateau
pressure is already lower than 30—35 cmH2O has not been
substantiated. Further research is necessary to demonstrate
the difference in benefit for these patients.
In conclusion, we found various risk factors associated
with hospital mortality in patients with ARF requiring MV
caused by PCP include APACHE II score on day 1, level of PEEP
on day 3, sex, and CMV co-infection, as well as history of prior
use of corticosteroid. Multimodality treatments, such as anti-
PCP prophylaxis in those patients at high risk of developing
PCP, aggressive work up for co-infection in non-responsive
patients, and protective lung ventilation strategies are
needed to improve survival.
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